Tumor growth suppression at TT is dependent on CD8+ T cells. Starting on the day of tumor implantation, (A and B) B16.F10 or (C and D) CT26, and every 4 d after, anti-CD8 was injected intraperitoneally to deplete CD8+ cells (A and C) or anti-IgG2 isotype control was injected intrapteritoneally (B and D). Data presented as mean ± SEM (n = 5; *P < 0.05, **P < 0.01, ***P < 0.001; Two-way ANOVA with Bonferroni posttests).